Society shapes science at every level, from which questions get asked to which answers are considered acceptable. The relationship runs deep: funding decisions, cultural values, political shifts, and even demographic biases all steer what gets studied, how it gets studied, and what happens with the results. Science never operates in a vacuum, and understanding these influences helps explain why certain fields advance rapidly while others stall for decades.
Funding Decides What Gets Studied
The most direct way society influences science is through money. Governments and private companies fund research, and their priorities reflect what society values, fears, or hopes to profit from. You might assume that funding flows toward the diseases and problems causing the most harm, but the reality is messier. A study published in PLOS One found that the actual burden a disease places on Americans (measured in disability and early death) explained only 33% of the variation in National Institutes of Health funding levels as of 2006. That figure had actually dropped from 39% a decade earlier, meaning funding alignment with public health needs got worse over time, not better.
What fills the gap? Charitable organizations and public advocacy play a measurable role. When researchers included disease-specific charity revenue alongside disease burden in their models, the two factors together explained 41% of NIH funding variation. In other words, diseases with well-organized, well-funded advocacy groups tend to attract more research dollars, regardless of whether they cause the most suffering overall. This means the ability of patient communities to fundraise, lobby, and generate media attention directly shapes which scientific questions get prioritized.
Economic Incentives Redirect Research
Market forces can reshape entire fields almost overnight. The U.S. Orphan Drug Act, passed in 1983, offered pharmaceutical companies tax credits, extended patents, and other financial incentives to develop treatments for rare diseases. Before the law, rare conditions were largely ignored because the potential customer base was too small to justify the investment. The shift has been dramatic: in the late 1980s, only about 5% of new drugs targeted rare diseases. By 2023, that number had climbed to 43%. A single piece of legislation, reflecting a societal decision that rare disease patients deserved treatment options, fundamentally altered where billions of research dollars flowed.
The flip side is that when society doesn’t create incentives, entire categories of disease can be neglected. Conditions that primarily affect people in low-income countries, for instance, have historically attracted far less pharmaceutical investment because the expected return is lower.
Politics Can Accelerate or Freeze Progress
Changes in political leadership can halt or restart entire research programs. Stem cell research in the United States is one of the clearest examples. During the Bush administration, NIH funding for embryonic stem cell research was banned for eight years. The restriction wasn’t based on a scientific determination that the research was unproductive. It reflected a political response to public concern that embryonic research violated human dignity, with many people equating embryos with human life. In March 2009, President Obama lifted the moratorium, and NIH released new guidelines for human stem cell research that took effect that July. In the years between, American researchers lost ground to international competitors, and some states, most notably California, passed their own legislation to fund the work independently.
Climate science has followed a similar pattern. Political administrations skeptical of climate regulation have targeted the scientific infrastructure behind climate policy. One current example involves efforts to reconsider the Endangerment Finding, the scientific and legal basis for regulating greenhouse gases under the Clean Air Act. Rescinding it would remove the federal government’s primary legal tool for limiting climate pollution. When long-serving independent experts are replaced, when scientific data becomes harder to access, and when political loyalty takes priority over expertise within agencies, the ability to produce and act on climate science erodes.
Cultural Values Shape What’s Permitted
Different societies draw different lines around what science is allowed to do, and those lines reflect cultural attitudes more than scientific evidence. Genetically modified organisms offer a stark case study. The United States has generally allowed GMO research and commercial development to proceed with relatively light regulation. Europe has taken the opposite approach, setting up regulatory frameworks so restrictive that a 2015 New York Times headline declared “Europe turns against science.” Critics argue the European framework fails basic criteria of scientific adaptability, meaning the rules don’t evolve as new evidence emerges. European institutions have also promoted and funded organic and conventional farming practices in developing countries, effectively steering agricultural science away from genetic modification on a global scale.
The consequences ripple outward. When a major economic bloc restricts a technology, researchers worldwide face reduced funding, fewer collaboration opportunities, and smaller markets for any resulting innovations. Consumer rejection of GMOs in Europe hasn’t just affected European science. It has increased costs, regulatory hurdles, and uncertainty for researchers everywhere working on transgenic crops.
Who Participates in Research Changes the Results
For most of modern medical history, clinical research was conducted primarily on white men. The assumption, rarely tested, was that results would apply equally to everyone. Society’s blind spots became science’s blind spots. It took an act of Congress to begin correcting this: the NIH Revitalization Act of 1993 wrote into federal law the requirement that women and minorities be included in all NIH-funded clinical research. The law went further, requiring that trials be designed so researchers could analyze whether treatments affected women and minorities differently than other participants. It also specified that cost could not be used as a reason to exclude these groups.
More recently, the FDA has begun requiring diversity action plans from companies seeking drug approval, mandating that sponsors outline how they will recruit participants from underrepresented populations. These policy changes reflect a broader societal recognition that science built on a narrow demographic produces knowledge with narrow applicability. Decades of medical research missed sex-specific differences in heart disease symptoms, drug metabolism, and pain perception simply because women weren’t adequately studied.
Public Opinion Sets Ethical Boundaries
Society doesn’t just influence which research gets funded. It determines which research is considered morally acceptable. The stem cell debate illustrates this clearly: public perception made no distinction between embryonic and fetal tissue, and the resulting moral framework treated all cell-based therapies as ethically equivalent. Researchers who had been working with fetal tissue for years suddenly found their work entangled in a controversy that had little to do with the biology and everything to do with how the public understood it.
This dynamic plays out with emerging technologies as well. The European Union’s AI Act, passed in 2024, includes exemptions for AI systems used solely for scientific research, placing them outside certain regulatory obligations. But applying those exemptions in practice has proven difficult, creating friction between the desire to regulate AI’s societal risks and the need to let researchers develop and test new systems. Every society negotiates this tension differently, and the negotiation itself determines how fast certain technologies advance.
Citizens Contribute Directly to Science
Society’s influence on science isn’t limited to top-down forces like funding and regulation. Ordinary people now contribute data that feeds directly into peer-reviewed research. A review of 334 scientific papers in the field of biodiversity found widespread use of data collected by non-scientists through community science programs. Birdwatchers logging sightings, hikers photographing plants, and hobbyists recording weather patterns all generate datasets that would be impossible for professional scientists to collect alone. The public’s willingness to participate, and the topics people find interesting enough to volunteer their time for, shapes which ecological questions can be answered with robust data.
This participation creates its own biases. Community science data tends to skew toward charismatic species like birds and butterflies, toward accessible geographic areas, and toward regions with higher internet connectivity. The result is that scientific knowledge of biodiversity reflects not just ecological reality but also which creatures and places society finds appealing enough to monitor.